Phaseline

Companies › Vertanical

Vertanical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VER-01
Cannabis sativa extract containing Δ9-tetrahydrocannabinol (THC) - cannabinoid receptor ag
CNR1, CNR2Phase 3Lumbosacral RadiculopathySep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06956014VER-01Phase 3Lumbosacral RadiculopathyOtherSep 2028

Targets

CNR1 (1) CNR2 (1)

Companies with the same targets

IGC Pharma Zynerba Pharmaceuticals Bazelet Nehushtan Incannex Healthcare Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix

Companies built like this

Zynerba Pharmaceuticals Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.